Scholar Rock Holding stock (US8063231019): Q1 EPS miss but shares rise 2.72%

Scholar Rock Holding reported Q1 2026 EPS of -$0.83, missing estimates by $0.03, yet the stock climbed 2.72% in pre-market trading amid FDA acceptance of its Biologics License Application.

Scholar Rock Holding disclosed its first-quarter 2026 earnings, posting an EPS of -$0.83, which fell short of forecasts by $0.03. Despite the miss, shares rose 2.72% in pre-market trading on May 14, 2026, buoyed by positive regulatory news as the FDA accepted the company's Biologics License Application for apitegromab, according to Investing.com as of 05/14/2026. This development highlights ongoing momentum in the biotech's pipeline.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Scholar Rock Holding Corporation
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe
• Key revenue drivers: Pipeline drug candidates
• Home exchange/listing venue: Nasdaq (SRRK)
• Trading currency: USD

Scholar Rock Holding: core business model

Scholar Rock Holding focuses on developing monoclonal antibodies targeting latent tissue growth factor-beta (TGF?) activation for fibrotic diseases and neuromuscular disorders. The company's lead candidate, apitegromab, targets spinal muscular atrophy (SMA), a rare neuromuscular condition. This precision approach differentiates Scholar Rock in the competitive biotech landscape, with clinical-stage assets driving value for US investors tracking neuromuscular therapies listed on Nasdaq.

Founded in 2012 and headquartered in Cambridge, Massachusetts, Scholar Rock leverages proprietary platforms to inhibit TGF? signaling without broad immunosuppression. As a clinical-stage biopharma, it has no approved products yet, relying on partnerships and milestones for funding. Its Nasdaq listing (SRRK) provides liquidity for US retail investors interested in rare disease innovation.

Main revenue and product drivers for Scholar Rock Holding

Apitegromab remains the primary value driver, advancing in Phase 3 for SMA as an adjunct to standard therapies. The recent FDA Biologics License Application acceptance marks a pivotal milestone, potentially unlocking peak sales in a US market exceeding $5 billion annually for SMA treatments, per industry estimates. Q1 2026 R&D expenses reflected ongoing trial investments, contributing to the EPS shortfall reported on May 14, 2026.

Pipeline diversification includes candidates for cardiometabolic and oncology indications. Revenue potential hinges on regulatory approvals and commercialization partnerships, with no Q1 sales reported as commercialization remains pre-revenue. US exposure is significant via domestic trials and the core SMA market.

Industry trends and competitive position

The neuromuscular disease sector sees robust growth, driven by gene therapies and biologics, with SMA treatments like Spinraza and Zolgensma setting high bars. Scholar Rock's apitegromab differentiates by enhancing motor function without replacing existing standards, positioning it for combination regimens. US biotech funding trends favor rare disease assets amid FDA incentives.

Why Scholar Rock Holding matters for US investors

Listed on Nasdaq, Scholar Rock offers US investors direct access to neuromuscular innovation amid a $10+ billion domestic rare disease market. Regulatory progress like the BLA acceptance signals potential near-term catalysts, aligning with biotech volatility that retail portfolios often track for growth exposure.

Conclusion

Scholar Rock Holding's Q1 2026 results showed an EPS miss offset by a 2.72% share gain and FDA BLA acceptance, underscoring pipeline progress in SMA. Investors monitor upcoming milestones amid biotech sector dynamics. The Nasdaq-listed stock remains focused on rare disease therapies with US market relevance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.